Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated:  11/30/2015
Massachusetts General Hospital SC-9
mi
from
Boston, MA
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated: 11/30/2015
Massachusetts General Hospital SC-9
mi
from
Boston, MA
Click here to add this to my saved trials
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated:  11/30/2015
University of California at Los Angeles UCLA SC
mi
from
Los Angeles, CA
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated: 11/30/2015
University of California at Los Angeles UCLA SC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated:  11/30/2015
University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8)
mi
from
Houston, TX
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated: 11/30/2015
University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8)
mi
from
Houston, TX
Click here to add this to my saved trials
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated:  11/30/2015
Novartis Investigative Site
mi
from
Singapore,
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Status: Enrolling
Updated: 11/30/2015
Novartis Investigative Site
mi
from
Singapore,
Click here to add this to my saved trials
The Women's Healthy Lifestyle Study
Motivational Interviewing for Weight Maintenance
Status: Enrolling
Updated:  11/30/2015
University of Michigan
mi
from
Ann Arbor, MI
The Women's Healthy Lifestyle Study
Motivational Interviewing for Weight Maintenance
Status: Enrolling
Updated: 11/30/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
TKI258 for Metastatic Inflammatory Breast Cancer Patients
A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse
Status: Enrolling
Updated:  12/1/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
TKI258 for Metastatic Inflammatory Breast Cancer Patients
A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse
Status: Enrolling
Updated: 12/1/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
A Pilot Study to Examine the Association Between Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
Status: Enrolling
Updated:  12/1/2015
Duke Cancer Center
mi
from
Durham, NC
Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
A Pilot Study to Examine the Association Between Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
Status: Enrolling
Updated: 12/1/2015
Duke Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Lifestyle Intervention for Breast Cancer Survivors
Targeting the Teachable Moment: A Lifestyle Intervention for Breast Cancer Survivors
Status: Enrolling
Updated:  12/2/2015
University of Connecticut
mi
from
Storrs, CT
A Lifestyle Intervention for Breast Cancer Survivors
Targeting the Teachable Moment: A Lifestyle Intervention for Breast Cancer Survivors
Status: Enrolling
Updated: 12/2/2015
University of Connecticut
mi
from
Storrs, CT
Click here to add this to my saved trials
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated:  12/2/2015
North Memorial Medical Center
mi
from
Minneapolis, MN
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated: 12/2/2015
North Memorial Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated:  12/2/2015
Fairview University
mi
from
Minneapolis, MN
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated: 12/2/2015
Fairview University
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated:  12/2/2015
Park Nicollet Institute
mi
from
St. Louis Park, MN
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated: 12/2/2015
Park Nicollet Institute
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Alabama Oncology
mi
from
Bessemer, AL
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Alabama Oncology
mi
from
Bessemer, AL
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
St. Jude Medical Center, Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
St. Jude Medical Center, Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
South Orange County Surgical Medical Group
mi
from
Laguna Hills, CA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
South Orange County Surgical Medical Group
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Cedars-Sinai Medical Center/Samuel Oschin Comprehensive Cancer institute
mi
from
Los Angeles, CA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Cedars-Sinai Medical Center/Samuel Oschin Comprehensive Cancer institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
University of Southern California - Norris Cancer Hospital
mi
from
Los Angeles, CA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
University of Southern California - Norris Cancer Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Moores UC San Diego Cancer Center (UCSD)
mi
from
San Diego, CA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Moores UC San Diego Cancer Center (UCSD)
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
University of California, San Francisco (UCSF), Hellen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
University of California, San Francisco (UCSF), Hellen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
University of Colorado Cancer Center, Anschutz Medical Campus
mi
from
Aurora, CO
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
University of Colorado Cancer Center, Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Holy Cross Hospital-Michael & Dianne Bienes Comprehensive Cancer Center
mi
from
Fort Lauderdale, FL
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Holy Cross Hospital-Michael & Dianne Bienes Comprehensive Cancer Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Cancer Specialists of North Florida (ICON)
mi
from
Jacksonville, FL
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Cancer Specialists of North Florida (ICON)
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
MD Anderson Center-Orlando health
mi
from
Orlando, FL
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
MD Anderson Center-Orlando health
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Florida Cancer Research Institute (Florida Cancer Care)
mi
from
Plantation, FL
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Florida Cancer Research Institute (Florida Cancer Care)
mi
from
Plantation, FL
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
H.Lee Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
H.Lee Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Central Georgia Cancer Care
mi
from
Macon, GA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Central Georgia Cancer Care
mi
from
Macon, GA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Northwestern University Feinberg School of Medicine, Lynn Sage Comprehensive Breast Center
mi
from
Chicago, IL
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Northwestern University Feinberg School of Medicine, Lynn Sage Comprehensive Breast Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Cancer Center of Kansas
mi
from
Wichita, KA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Mary Bird Perkins Cancer Center
mi
from
Baton Rouge, LA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Mary Bird Perkins Cancer Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Center of Cancer and Blood Disorders (VEEDA network)
mi
from
Bethesda, MD
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Center of Cancer and Blood Disorders (VEEDA network)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Lahey Clinic Department of Hematology and Oncology
mi
from
Burlington, MA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Lahey Clinic Department of Hematology and Oncology
mi
from
Burlington, MA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
William Beaumont Hospital Cancer Center
mi
from
Royal Oak, MI
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
William Beaumont Hospital Cancer Center
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Eastchester Cancer Care Center
mi
from
Bronx, NY
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Eastchester Cancer Care Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
St. Alexius Medical Center, Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
St. Alexius Medical Center, Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Conemaugh Memorial Hospital-Memorial Medical Center
mi
from
Johnstown, PA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Conemaugh Memorial Hospital-Memorial Medical Center
mi
from
Johnstown, PA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
University of Pittsburgh Medical Center (UPMC) Cancer Center
mi
from
Pittsburgh, PA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
University of Pittsburgh Medical Center (UPMC) Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
The West Clinic, PC
mi
from
Memphis, TN
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
UT Southwestern Medical Center / Simmons Comprehensive Cancer Center
mi
from
Dallas, TX
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
UT Southwestern Medical Center / Simmons Comprehensive Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Brooke Army Medical Center (now SAMMC)
mi
from
Ft. Sam Houston, TX
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Brooke Army Medical Center (now SAMMC)
mi
from
Ft. Sam Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Swedish Cancer Institute Research
mi
from
Seattle, WA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Swedish Cancer Institute Research
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
MultiCare Health System Research Institute
mi
from
Tacoma, WA
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
MultiCare Health System Research Institute
mi
from
Tacoma, WA
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Medical College of Wisconsin Department of Surgery Froedtert Hospital and Cancer Center
mi
from
Milwaukee, WI
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Medical College of Wisconsin Department of Surgery Froedtert Hospital and Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated:  12/3/2015
Weill-Cornell Medical College
mi
from
New York, NY
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment
Status: Enrolling
Updated: 12/3/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials